Photo taken from EORTC/LinkedIn
Aug 21, 2024, 14:16
EORTC – Understanding long-term quality of life after completion of an adjuvant treatment for melanoma
EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:
” Have you read our latest publication in The Lancet Oncology?
Understanding patients’ health-related quality of life after completion of an adjuvant treatment for melanoma is important.
The research area concerns patients who are likely to become cancer survivors and would be impacted by potential long-term adverse effects. This publication provides results on the long-term health-related quality of life of melanoma patients treated with a PD-1 inhibitor. ”
Authors: Emanuel Bührer, Michal Kicinski, Mario Mandala, Madeline Pe, Prof Georgina V Long, Victoria Atkinson, Christian U Blank, Andrew Haydon, Prof Stéphane Dalle, Adnan Khattak, Matteo S Carlino, Prof Andrey Meshcheryakov, Prof Shahneen Sandhu, Prof Susana Puig, Prof Dirk Schadendorf, Rahima Jamal, Prof Piotr Rutkowski, Prof Alfonsus J M van den Eertwegh, Corneel Coens, Dmitri Grebennik, Clemens Krepler, Prof Caroline Robert, Prof Alexander M M Eggermont.
Source: EORTC/LinkedIn
Adnan Khattak
Andrew Haydon
cancer
Christian U. Blank
Clemens Krepler
Corneel Coens
Dmitri Grebennik
Emanuel Bührer
EORTC
Madeline Pe
Mario Mandala
Matteo S Carlino
Melanoma
Michal Kicinski
OncoDaily
Oncology
Prof Alexander M M Eggermont
Prof Alfonsus J M van den Eertwegh
Prof Andrey Meshcheryakov
Prof Caroline Robert
Prof Dirk Schadendorf
Prof Georgina V Long
Prof Piotr Rutkowski
Prof Shahneen Sandhu
Prof Stéphane Dalle
Prof Susana Puig
Rahima Jamal
The Lancet Oncology
Victoria Atkinson
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18